IRIS
MALCOVATI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.296
EU - Europa 2.512
AS - Asia 1.808
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 9
OC - Oceania 8
SA - Sud America 3
Totale 8.647
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.269
CN - Cina 1.698
IE - Irlanda 866
UA - Ucraina 418
FI - Finlandia 380
DE - Germania 237
IT - Italia 233
SE - Svezia 175
GB - Regno Unito 97
SG - Singapore 64
FR - Francia 39
RU - Federazione Russa 26
CA - Canada 25
BE - Belgio 21
JP - Giappone 20
EU - Europa 10
AU - Australia 8
IN - India 7
MU - Mauritius 6
NL - Olanda 6
IL - Israele 5
CH - Svizzera 4
HK - Hong Kong 4
TR - Turchia 4
ES - Italia 3
GR - Grecia 3
BR - Brasile 2
IR - Iran 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
BD - Bangladesh 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EG - Egitto 1
ID - Indonesia 1
IQ - Iraq 1
MX - Messico 1
PA - Panama 1
PL - Polonia 1
SA - Arabia Saudita 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 8.647
Salva come PNG Salva come JPEG
Città #
Chandler 911
Dublin 866
Jacksonville 582
Nanjing 522
Boardman 369
Ashburn 338
Princeton 211
Lawrence 197
Nanchang 196
Medford 184
Wilmington 170
Hebei 145
Changsha 140
Shenyang 137
Jiaxing 119
Helsinki 104
Beijing 100
New York 93
Ann Arbor 84
Tianjin 80
Hangzhou 78
Milan 61
Shanghai 56
Pavia 54
Seattle 47
Woodbridge 38
Norwalk 35
Singapore 35
Washington 24
Fairfield 22
Brussels 21
Verona 21
Toronto 19
Tokyo 18
Falls Church 16
Des Moines 13
Los Angeles 13
Zhengzhou 12
Chicago 11
Dearborn 11
Jinan 11
Kunming 11
Redwood City 11
Ningbo 10
San Francisco 8
Taizhou 8
Dallas 6
Fuzhou 6
Guangzhou 6
Houston 6
Santa Clara 5
Tappahannock 5
Auburn Hills 4
Brignano Gera D'adda 4
Canberra 4
Hong Kong 4
Leawood 4
Novokuznetsk 4
Redmond 4
Sacramento 4
Andover 3
Brugherio 3
Kemerovo 3
Lugano 3
Morbegno 3
Orange 3
Rochester 3
Salamanca 3
Taranto 3
Winnipeg 3
Acre 2
Berlin 2
Boston 2
Busto Arsizio 2
Casatenovo 2
Catania 2
Chengdu 2
Falkenstein 2
Gießen 2
Hefei 2
Krasnoyarsk 2
Lanzhou 2
Melbourne 2
Monza 2
Naples 2
Paullo 2
Pune 2
Reston 2
Sesto San Giovanni 2
São Paulo 2
Tel Aviv 2
Wuhan 2
Yongzhou 2
Adelaide 1
Agra 1
Alghero 1
Amsterdam 1
Andorno Micca 1
Borås 1
Buffalo 1
Totale 6.361
Salva come PNG Salva come JPEG
Nome #
Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. 87
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 83
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 79
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 78
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 74
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 72
Assessment of chimerism in sex-mismatched allogeneic bone marrrow transplants (allo-BMT) by in situ hybridization and cytogenetics. Is host cell percentage predictive of relapse? 71
Myelodysplastic syndromes: diagnosis and staging. 71
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 71
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 70
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. 70
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 69
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 69
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 68
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 68
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 68
Classification and prognostic evaluation of myelodysplastic syndromes 68
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 66
Peripheral arterial vascular function at altitude: sea-level natives versus Himalayan high-altitude natives 65
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 64
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 64
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms 64
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 64
Clinical significance of somatic mutation in unexplained blood cytopenia 64
Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. 64
Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse 63
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes 63
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). 62
Clinical and biological implications of driver mutations in myelodysplastic syndromes 61
Hematologic passport for athletes competing in endurance sports: a feasibility study. 60
Clinical evaluation of extra-hematological comorbidity in myelodysplastic syndromes: "ready-to-wear" versus "made-to-measure" tools. 60
Revised international prognostic scoring system for myelodysplastic syndromes 60
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 59
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 59
Morphological features and prognostic implication in a retrospective analysis of 370 patients with myelodysplastic syndrome 59
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 59
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 58
A novel t(Y;11) translocation with MLL gene rearrangement in a case of acute myelomonocytic leukemia (AML-M4) 58
Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. 58
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 58
Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse 58
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 58
Myelodysplastic/myeloproliferative disorders 57
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome 57
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 57
Cerebral vasoreactivity in Andeans and headache at sea level. 56
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 56
Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes 56
Predicting survival and leukemic evolution in patients with myelodysplastic syndrome 56
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. 56
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. 55
Effects of breathing control on cardiocirculatory modulation in Caucasian lowlanders and Himalayan Sherpas 55
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. 55
Simian virus 40 and lymphoproliferative disorder. 54
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 54
Myelodysplastic/myeloproliferative neoplasms 54
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 54
Fournier's gangrene: a clinical presentation of necrotizing fasciitis after bone marrow transplantation. 54
Genetic and clinical heterogeneity of ferroportin disease. 54
Risk factors for Gram-negative infections in neutropenic patients. 54
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 54
Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. 53
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. 53
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms 53
A complex translocation (5;7) in a patient with acute nonlymphocytic leukemia evolved from a myelodysplastic syndrome. 53
Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy? 52
Splenectomy for treatment of immune thrombocytopenic purpura. 52
Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. 52
CHARACTERIZATION OF A CELLULAR MODEL FOR THE STUDY OF MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 51
From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging. 50
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome 50
Novel homeobox gene recombination in T-cell acute lymphoblastic leukemia. 50
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 50
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome 49
The genetic basis of myelodysplasia and its clinical relevance 49
Aplastic anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2010. 49
Myelodysplastic syndromes--coping with ineffective hematopoiesis. 49
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. 49
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 49
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. 48
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. 48
Myelodysplastic syndromes with bone marrow fibrosis. 48
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia 48
Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. 47
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 47
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis 46
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. 46
Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications 46
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype 46
Cytogenetic and FISH analyses in five patients with hypoplastic bone marrow. 45
THE IMPACT OF THE DEGREE OF ANEMIA ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROME. A BASIS FOR PROGNOSTIC ASSESSMENT AND CLINICAL DECISION MAKING 45
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions 45
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 44
High incidence of symptomatic cytomegalovirus infection in multiple myeloma patients undergoing autologous peripheral blood stm cell transplantation. 44
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 44
Hypereosinophilic syndrome and cyclic oscillations in blood cell counts. A clonal disorder of hematopoiesis originating in a pluripotent stem cell. 44
Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. 44
Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. 44
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. 43
Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need 43
Totale 5.680
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.179
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.179
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.320 0 823 4 75 4 87 14 86 6 123 95 3
2020/2021860 102 68 20 80 4 91 46 152 28 140 95 34
2021/2022918 15 4 15 15 34 34 12 42 57 34 143 513
2022/20232.557 273 138 20 234 248 264 2 165 1.053 25 96 39
2023/20241.166 85 199 58 79 113 332 29 69 10 23 78 91
2024/2025352 75 277 0 0 0 0 0 0 0 0 0 0
Totale 9.073